TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03257423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem followed by levofloxacin and metronidazole
Description: Ertapenem 1 g i.v. daily for either 2 days (MAPPAC + APPAC II patients) or 3 days (MAPPAC + APPAC III) followed by p.o. levofloxacin 500 mg x 1 + metronidazole 500 mg x 3 for either 5 days (APPAC II + MAPPAC) or 4 days (APPAC III + MAPPAC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem followed by levofloxacin and metronidazole
Description: Ertapenem 1 g i.v. daily for either 2 days (MAPPAC + APPAC II patients) or 3 days (MAPPAC + APPAC III) followed by p.o. levofloxacin 500 mg x 1 + metronidazole 500 mg x 3 for either 5 days (APPAC II + MAPPAC) or 4 days (APPAC III + MAPPAC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg once a day for seven days (APPAC II + MAPPAC)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Appendectomy
Description: Primarily laparoscopic appendectomy for either complicated acute appendicitis or uncomplicated acute appendicitis (refusing to participate in APPAC II or III trials or recurrent acute appendicitis).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Appendectomy
Description: Primarily laparoscopic appendectomy for either complicated acute appendicitis or uncomplicated acute appendicitis (refusing to participate in APPAC II or III trials or recurrent acute appendicitis).
Study: NCT04943809

Intervention type: DEVICE
Intervention: POD 26P AY F
Description: Routine cataract surgery
Study: NCT03081767

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital PET/CT scan
Description: The Division of Nuclear Medicine and Molecular Imaging at Stanford has installed the first ever GE-made digital PET/CT scanner worldwide. The investigators wish to determine if the digital PET/CT scanner offers equivalent image quality as the standard PET/CT scanner.
Study: NCT01578174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -\> 2㎍/mL) : the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal saline 100mL(guess as 2㎍/mL):the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
Study: NCT00820456

Intervention type: OTHER
Intervention: DCE-MRI
Description: Participants will receive two (2) dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) prior to chemotherapy and one (1) DCE-MRI after the first cycle of chemotherapy. Participants will be followed for up to 2 years after the initiation of chemotherapy or until disease progression.

Intervention type: OTHER
Intervention: DCE-MRI
Description: Participants will receive two (2) dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) prior to chemotherapy and one (1) DCE-MRI after the first cycle of chemotherapy. Participants will be followed for up to 2 years after the initiation of chemotherapy or until disease progression.
Study: NCT02699580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lateral rectus recession with biodegradable collagen implant
Description: Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done. After lateral rectus recession, no degradable collagen implant was placed in the area, where lateral rectus was original inserted. One eye was randomly selected for the comparison.
Study: NCT03257423

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo i.v. once a day for three days (APPAC III + MAPPAC) followed by placebo capsules three times a day for four days.
Study: NCT01731587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: MUC1 peptide specific immunotherapy
Description: Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals, commencing at Week 14, until disease progression is documented.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPA)
Description: A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.
Study: NCT02632019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study: NCT02699580

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral rectus recession without biodegradable collagen implantation
Description: Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done in the other eye without placing biodegradable collagen implantation.
Study: NCT02632019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell-precision T cell for neo-antigen combined with gemcitabine treatment
Description: Gemcitabine: Gemcitabine 1000mg/m2, Physiological saline 100ml: IV (in the vein) once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.~PNAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study: NCT02249884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea Dose A
Description: Urea cream for topical use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea Dose B
Description: Urea cream for topical use.
Study: NCT00003143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine

Intervention type: DRUG
Group type: OTHER
Intervention: DHAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHAP
Study: NCT00128622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denileukin diftitox
Study: NCT01647191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention group
Description: The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: The investigators will adopt previous treatment in the clinics to intervent the patients
Study: NCT01607229

Intervention type: OTHER
Intervention: observation
Description: no intervention used, observed measurements from 3 test devices compared to reference criterion measurement for total body water and body composition
Study: NCT01566942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: In this arm, patients will receive the adjuvant chemotherapy with mFOLFOX6 regimen for 8 cycles. Oxaliplatin 85mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
Study: NCT00128622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Study: NCT01170884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution
Description: 1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (Combigan®) taken approximately 12 hours apart, up to 2 times a day and 1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken once every 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
Description: 1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken approximately every 24 hours; mild lubricant eyedrops (Gen Teal® Mild) for masking purposes
Study: NCT02487940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
Study: NCT04175353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy snack
Description: The effects of dairy snack are compared with orange juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy snack
Description: The effects of dairy snack are compared with orange juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry snack
Description: The effects of two berry snacks are compared with berry soup.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry snack
Description: The effects of two berry snacks are compared with berry soup.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berry snack
Description: The effects of two berry snacks are compared with berry soup.
Study: NCT02249884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea Dose C
Description: Urea cream for topical use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chamomile Dose A
Description: Chamomile gel for topical use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chamomile Dose B
Description: Chamomile gel for topical use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chamomile Dose C
Description: Chamomile gel for topical use.
Study: NCT02730715

Intervention type: DRUG
Intervention: Basiliximab
Description: Periodic blood collection to monitor Treg cells

Intervention type: DRUG
Intervention: Thymoglobulin
Description: Periodic blood collection to monitor Treg cells
Study: NCT04384172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tibial e-stim
Description: For tibial nerve stimulation, the two electrodes will be placed just above the medial malleolus and the ipsilateral calcaneus on one leg near the ankle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tibial e-stim
Description: For tibial nerve stimulation, the two electrodes will be placed just above the medial malleolus and the ipsilateral calcaneus on one leg near the ankle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genital e-stim
Description: For dorsal genital nerve stimulation, two electrodes will be placed on either side of the clitoris.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genital e-stim
Description: For dorsal genital nerve stimulation, two electrodes will be placed on either side of the clitoris.
Study: NCT04188483

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium Supplementation
Description: The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza vaccination
Description: Subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
Study: NCT02337933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolic acid
Description: Ursolic acid capsules of 150 mg extracted from rosemary, once a day before breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Calcined magnesia capsules of 150 mg, once a day before breakfast
Study: NCT03554096

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
Study: NCT04299854

Intervention type: DRUG
Intervention: Dinoprostone 10mg
Description: Vaginal delivery system containing 10mg of dinoprostone placed at the bottom of the vagina

Intervention type: DEVICE
Intervention: single balloon Foley catheter
Description: A single balloon Foley catheter is being inserted on transcervical and inflated above the internal cervical os
Study: NCT04606563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Oral losartan 25 mg, stepped up to 50 mg and then up to 100 mg peak dose, as tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Oral Valsartan 40 mg, stepped up to 80 mg and then up to 160 mg peak dose, as tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Oral Azilsartan 40 mg, and stepped up to 80 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Oral Candesartan 8 mg, stepped up to 16 mg and then up to 32 mg peak dose, as tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprosartan
Description: Oral Eprosartan 400 mg, stepped up to 600 mg and then up to 800 mg peak dose, as tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Oral Irbesartan 75 mg, stepped up to 150 mg and then up to 300 mg peak dose, as tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Description: Oral Olmesartan 10 mg, stepped up to 20 mg and then up to 40 mg peak dose, as tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Oral Azilsartan 40 mg, and stepped up to 80 mg.
Study: NCT00803959

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Office evaluation
Description: Office evaluation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Office evaluation
Description: Office evaluation
Study: NCT01319227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip replacement
Description: Hip arthroplasty with uncemented components
Study: NCT04188483

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Description: Subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
Study: NCT00803959

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UDS
Description: Urodynamics
Study: NCT01182233

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Skeletal Irradiation
Description: Escalating doses of TSI starting at 200cGy (escalating up to 400cGy unless maximum tolerated dose is determined in lower dose level) in cohort 1 over 5 days followed by high dose melphalan and cytoprotection followed by autologous hematopoietic stem cell transplant
Study: NCT01519583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic Intervention
Description: Participants will have the goal of obtaining 10,000 steps/day. In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and staff will provide a behavioral intervention to improve physical activity levels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Pedometry
Description: Intensity Enhanced Pedometry: Participants will have the goal of obtaining 10,000 steps/day at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min). In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and the staff will provide a behavioral intervention to improve physical activity levels.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Maintain usual physical activity, and return for follow-up measures.
Study: NCT03765073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Group B streptococcus vaccine
Description: Various formulations at three dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Group B streptococcus vaccine
Description: Various formulations at three dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Group B streptococcus vaccine
Description: Various formulations at three dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Group B streptococcus vaccine
Description: Various formulations at three dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Group B streptococcus vaccine
Description: Various formulations at three dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Group B streptococcus vaccine
Description: Various formulations at three dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Group B streptococcus vaccine
Description: Various formulations at three dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Group B streptococcus vaccine
Description: Various formulations at three dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Group B streptococcus vaccine
Description: Various formulations at three dose levels

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline control

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline control
Study: NCT01566942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: In this arm, patients will receive the adjuvant chemotherapy with FOLFIRI regimen for 8 cycles. Irinotecan 180mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
Study: NCT02481271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation program
Description: relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation program
Description: relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: surgery education
Description: intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: surgery education
Description: intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery
Study: NCT01639066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tenofovir 300mg daily Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir 1 mg daily Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir 300mg daily Oral
Study: NCT00811824

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity and dietary change
Description: 6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity and dietary change
Description: 6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class
Study: NCT00402532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Initial dosage 2 x 0.75 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolatmofetil
Description: Initial dosage 2 x 500 mg/d intravenous
Study: NCT02967913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder flap
Description: bladder is separated from the lower uterine segment prior to making the uterine incision at time of cesarean delivery
Study: NCT04929366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermic dialysis followed with routine dialysis
Description: Hypothermic dialysis (35.5 degrees Celsius dialysate) followed with routine dialysis (36.5 degrees Celsius dialysate)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine dialysis followed with hypothermic dialysis
Description: Routine dialysis (36.5 degrees Celsius dialysate) followed with hypothermic dialysis (35.5 degrees Celsius dialysate)
Study: NCT00697541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.18% COL-118 facial gel (1.8 mg brimonidine)
Description: One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)
Description: One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advanced Eye Relief
Description: One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COL-118 facial gel vehicle
Description: One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically